Loading…

Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study

IntroductionPeople who inject drugs (PWID) have remained a contributor to the consistent HIV incidence rates in the US for decades. Pre-exposure prophylaxis (PrEP) is a promising biomedical intervention for HIV prevention among individuals at risk for HIV infection, including PWID. However, PWID rep...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2023-06, Vol.13 (6), p.e071688-e071688
Main Authors: Mistler, Colleen B, Shrestha, Roman, Gunstad, John, Collins, Linda, Madden, Lynn, Huedo-Medina, Tania, Sibilio, Brian, Copenhaver, Nicholas M, Copenhaver, Michael
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-b490t-3078f8fd64fedb51f901dcb0d1927914092695139999024dc51b1cc8296a137a3
container_end_page e071688
container_issue 6
container_start_page e071688
container_title BMJ open
container_volume 13
creator Mistler, Colleen B
Shrestha, Roman
Gunstad, John
Collins, Linda
Madden, Lynn
Huedo-Medina, Tania
Sibilio, Brian
Copenhaver, Nicholas M
Copenhaver, Michael
description IntroductionPeople who inject drugs (PWID) have remained a contributor to the consistent HIV incidence rates in the US for decades. Pre-exposure prophylaxis (PrEP) is a promising biomedical intervention for HIV prevention among individuals at risk for HIV infection, including PWID. However, PWID report the lowest rates of PrEP uptake and adherence among at-risk groups. Tailored HIV prevention interventions must include strategies that compensate for cognitive dysfunction among PWID.Methods and analysisUsing the multiphase optimisation strategy, we will be conducting a 16-condition factorial experiment to investigate the effects of four different accommodation strategy components to compensate for cognitive dysfunction among 256 PWID on medication for opioid use disorder. This innovative approach will inform optimisation of a highly effective intervention to enhance PWID’s ability to process and utilise HIV prevention content to improve PrEP adherence and HIV risk reduction in a drug treatment setting.Ethics and disseminationThe institutional review board at the University of Connecticut approved this protocol (H22-0122) with an institutional reliance agreement with APT Foundation Inc. All participants are required to sign an informed consent form prior to engaging in any study protocols. The results of this study will be disseminated on national and international platforms through presentations at major conferences and journals.Trial registration numberNCT05669534.
doi_str_mv 10.1136/bmjopen-2023-071688
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8f1612daf38c4c329a45e8cd0321f776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_8f1612daf38c4c329a45e8cd0321f776</doaj_id><sourcerecordid>2833023056</sourcerecordid><originalsourceid>FETCH-LOGICAL-b490t-3078f8fd64fedb51f901dcb0d1927914092695139999024dc51b1cc8296a137a3</originalsourceid><addsrcrecordid>eNp9kstu1DAUhiMEolXpEyAhS2zaRahvuZgNqsqlIxV1QcvWcnzJeJSJg-1MNQ_JO-FMZkrLgmxi-fz_d05O_ix7i-AHhEh50axXbtB9jiEmOaxQWdcvsmMMKc1LWBQvn5yPstMQVjA9tGBFgV9nR6QijFFaHWe_L4ehs1JE63rgDIhLDdZjF-2wFEEDN0S7tmEuh-hF1O0WnH2__XF3DqI71DW4XvwEg9cb3e-kUfhWR9u3YNBu6BKoB2utDo2M88lqnVVgTGZlg_NK-wl8__kcPCwdWIqNBtK1vY02ndQ2mLGXk_tjauSik67bcQSYpknDjWr7JntlRBf06f59kt1__XJ3dZ3f3H5bXF3e5A1lMOYEVrWpjSqp0aopkGEQKdlAhRiuGKKQ4ZIVKO2IMYipkgVqkJQ1ZqVApBLkJFvMXOXEig_eroXfcics310433Lho5Wd5rVBJcJKGFJLKglmgha6lgoSjExVlYn1aWYNY5NWJNMGveieQZ9XervkrdtwBAmiJa0T4WxP8O7XqEPk6ZdI3XWi124MHNeEpJjAYmr2_h_pyo2-T7uaVKisaEImFZlV0rsQvDaP0yDIp_jxffz4FD8-xy-53j39kEfPIWxJcDELkvtv3_8h_wDflOnc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2831674146</pqid></control><display><type>article</type><title>Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study</title><source>BMJ Open Access Journals</source><source>Publicly Available Content Database</source><source>BMJ Journals</source><source>PubMed Central</source><creator>Mistler, Colleen B ; Shrestha, Roman ; Gunstad, John ; Collins, Linda ; Madden, Lynn ; Huedo-Medina, Tania ; Sibilio, Brian ; Copenhaver, Nicholas M ; Copenhaver, Michael</creator><creatorcontrib>Mistler, Colleen B ; Shrestha, Roman ; Gunstad, John ; Collins, Linda ; Madden, Lynn ; Huedo-Medina, Tania ; Sibilio, Brian ; Copenhaver, Nicholas M ; Copenhaver, Michael</creatorcontrib><description>IntroductionPeople who inject drugs (PWID) have remained a contributor to the consistent HIV incidence rates in the US for decades. Pre-exposure prophylaxis (PrEP) is a promising biomedical intervention for HIV prevention among individuals at risk for HIV infection, including PWID. However, PWID report the lowest rates of PrEP uptake and adherence among at-risk groups. Tailored HIV prevention interventions must include strategies that compensate for cognitive dysfunction among PWID.Methods and analysisUsing the multiphase optimisation strategy, we will be conducting a 16-condition factorial experiment to investigate the effects of four different accommodation strategy components to compensate for cognitive dysfunction among 256 PWID on medication for opioid use disorder. This innovative approach will inform optimisation of a highly effective intervention to enhance PWID’s ability to process and utilise HIV prevention content to improve PrEP adherence and HIV risk reduction in a drug treatment setting.Ethics and disseminationThe institutional review board at the University of Connecticut approved this protocol (H22-0122) with an institutional reliance agreement with APT Foundation Inc. All participants are required to sign an informed consent form prior to engaging in any study protocols. The results of this study will be disseminated on national and international platforms through presentations at major conferences and journals.Trial registration numberNCT05669534.</description><identifier>ISSN: 2044-6055</identifier><identifier>EISSN: 2044-6055</identifier><identifier>DOI: 10.1136/bmjopen-2023-071688</identifier><identifier>PMID: 37399447</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Anti-HIV Agents - therapeutic use ; Behavior ; Cognitive Dysfunction - drug therapy ; Cognitive Dysfunction - prevention &amp; control ; Disease prevention ; Drug use ; Executive function ; Factorial experiments ; HIV ; HIV Infections - drug therapy ; HIV Infections - prevention &amp; control ; HIV/AIDS ; Human immunodeficiency virus ; Humans ; Infectious disease/HIV ; Information processing ; Intervention ; Memory ; Narcotics ; Opioid-Related Disorders - drug therapy ; Opioid-Related Disorders - prevention &amp; control ; Pre-Exposure Prophylaxis - methods ; STATISTICS &amp; RESEARCH METHODS ; Substance Abuse, Intravenous - epidemiology ; Substance misuse ; Substance use disorder</subject><ispartof>BMJ open, 2023-06, Vol.13 (6), p.e071688-e071688</ispartof><rights>Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-b490t-3078f8fd64fedb51f901dcb0d1927914092695139999024dc51b1cc8296a137a3</cites><orcidid>0000-0002-8681-0252</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2831674146/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2831674146?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3192,25752,27923,27924,37011,37012,44589,53790,53792,55340,55349,74897,77367,77368,77431,77457</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37399447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mistler, Colleen B</creatorcontrib><creatorcontrib>Shrestha, Roman</creatorcontrib><creatorcontrib>Gunstad, John</creatorcontrib><creatorcontrib>Collins, Linda</creatorcontrib><creatorcontrib>Madden, Lynn</creatorcontrib><creatorcontrib>Huedo-Medina, Tania</creatorcontrib><creatorcontrib>Sibilio, Brian</creatorcontrib><creatorcontrib>Copenhaver, Nicholas M</creatorcontrib><creatorcontrib>Copenhaver, Michael</creatorcontrib><title>Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study</title><title>BMJ open</title><addtitle>BMJ Open</addtitle><addtitle>BMJ Open</addtitle><description>IntroductionPeople who inject drugs (PWID) have remained a contributor to the consistent HIV incidence rates in the US for decades. Pre-exposure prophylaxis (PrEP) is a promising biomedical intervention for HIV prevention among individuals at risk for HIV infection, including PWID. However, PWID report the lowest rates of PrEP uptake and adherence among at-risk groups. Tailored HIV prevention interventions must include strategies that compensate for cognitive dysfunction among PWID.Methods and analysisUsing the multiphase optimisation strategy, we will be conducting a 16-condition factorial experiment to investigate the effects of four different accommodation strategy components to compensate for cognitive dysfunction among 256 PWID on medication for opioid use disorder. This innovative approach will inform optimisation of a highly effective intervention to enhance PWID’s ability to process and utilise HIV prevention content to improve PrEP adherence and HIV risk reduction in a drug treatment setting.Ethics and disseminationThe institutional review board at the University of Connecticut approved this protocol (H22-0122) with an institutional reliance agreement with APT Foundation Inc. All participants are required to sign an informed consent form prior to engaging in any study protocols. The results of this study will be disseminated on national and international platforms through presentations at major conferences and journals.Trial registration numberNCT05669534.</description><subject>Anti-HIV Agents - therapeutic use</subject><subject>Behavior</subject><subject>Cognitive Dysfunction - drug therapy</subject><subject>Cognitive Dysfunction - prevention &amp; control</subject><subject>Disease prevention</subject><subject>Drug use</subject><subject>Executive function</subject><subject>Factorial experiments</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - prevention &amp; control</subject><subject>HIV/AIDS</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infectious disease/HIV</subject><subject>Information processing</subject><subject>Intervention</subject><subject>Memory</subject><subject>Narcotics</subject><subject>Opioid-Related Disorders - drug therapy</subject><subject>Opioid-Related Disorders - prevention &amp; control</subject><subject>Pre-Exposure Prophylaxis - methods</subject><subject>STATISTICS &amp; RESEARCH METHODS</subject><subject>Substance Abuse, Intravenous - epidemiology</subject><subject>Substance misuse</subject><subject>Substance use disorder</subject><issn>2044-6055</issn><issn>2044-6055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kstu1DAUhiMEolXpEyAhS2zaRahvuZgNqsqlIxV1QcvWcnzJeJSJg-1MNQ_JO-FMZkrLgmxi-fz_d05O_ix7i-AHhEh50axXbtB9jiEmOaxQWdcvsmMMKc1LWBQvn5yPstMQVjA9tGBFgV9nR6QijFFaHWe_L4ehs1JE63rgDIhLDdZjF-2wFEEDN0S7tmEuh-hF1O0WnH2__XF3DqI71DW4XvwEg9cb3e-kUfhWR9u3YNBu6BKoB2utDo2M88lqnVVgTGZlg_NK-wl8__kcPCwdWIqNBtK1vY02ndQ2mLGXk_tjauSik67bcQSYpknDjWr7JntlRBf06f59kt1__XJ3dZ3f3H5bXF3e5A1lMOYEVrWpjSqp0aopkGEQKdlAhRiuGKKQ4ZIVKO2IMYipkgVqkJQ1ZqVApBLkJFvMXOXEig_eroXfcics310433Lho5Wd5rVBJcJKGFJLKglmgha6lgoSjExVlYn1aWYNY5NWJNMGveieQZ9XervkrdtwBAmiJa0T4WxP8O7XqEPk6ZdI3XWi124MHNeEpJjAYmr2_h_pyo2-T7uaVKisaEImFZlV0rsQvDaP0yDIp_jxffz4FD8-xy-53j39kEfPIWxJcDELkvtv3_8h_wDflOnc</recordid><startdate>20230630</startdate><enddate>20230630</enddate><creator>Mistler, Colleen B</creator><creator>Shrestha, Roman</creator><creator>Gunstad, John</creator><creator>Collins, Linda</creator><creator>Madden, Lynn</creator><creator>Huedo-Medina, Tania</creator><creator>Sibilio, Brian</creator><creator>Copenhaver, Nicholas M</creator><creator>Copenhaver, Michael</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8681-0252</orcidid></search><sort><creationdate>20230630</creationdate><title>Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study</title><author>Mistler, Colleen B ; Shrestha, Roman ; Gunstad, John ; Collins, Linda ; Madden, Lynn ; Huedo-Medina, Tania ; Sibilio, Brian ; Copenhaver, Nicholas M ; Copenhaver, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b490t-3078f8fd64fedb51f901dcb0d1927914092695139999024dc51b1cc8296a137a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-HIV Agents - therapeutic use</topic><topic>Behavior</topic><topic>Cognitive Dysfunction - drug therapy</topic><topic>Cognitive Dysfunction - prevention &amp; control</topic><topic>Disease prevention</topic><topic>Drug use</topic><topic>Executive function</topic><topic>Factorial experiments</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - prevention &amp; control</topic><topic>HIV/AIDS</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infectious disease/HIV</topic><topic>Information processing</topic><topic>Intervention</topic><topic>Memory</topic><topic>Narcotics</topic><topic>Opioid-Related Disorders - drug therapy</topic><topic>Opioid-Related Disorders - prevention &amp; control</topic><topic>Pre-Exposure Prophylaxis - methods</topic><topic>STATISTICS &amp; RESEARCH METHODS</topic><topic>Substance Abuse, Intravenous - epidemiology</topic><topic>Substance misuse</topic><topic>Substance use disorder</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mistler, Colleen B</creatorcontrib><creatorcontrib>Shrestha, Roman</creatorcontrib><creatorcontrib>Gunstad, John</creatorcontrib><creatorcontrib>Collins, Linda</creatorcontrib><creatorcontrib>Madden, Lynn</creatorcontrib><creatorcontrib>Huedo-Medina, Tania</creatorcontrib><creatorcontrib>Sibilio, Brian</creatorcontrib><creatorcontrib>Copenhaver, Nicholas M</creatorcontrib><creatorcontrib>Copenhaver, Michael</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>BMJ open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mistler, Colleen B</au><au>Shrestha, Roman</au><au>Gunstad, John</au><au>Collins, Linda</au><au>Madden, Lynn</au><au>Huedo-Medina, Tania</au><au>Sibilio, Brian</au><au>Copenhaver, Nicholas M</au><au>Copenhaver, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study</atitle><jtitle>BMJ open</jtitle><stitle>BMJ Open</stitle><addtitle>BMJ Open</addtitle><date>2023-06-30</date><risdate>2023</risdate><volume>13</volume><issue>6</issue><spage>e071688</spage><epage>e071688</epage><pages>e071688-e071688</pages><issn>2044-6055</issn><eissn>2044-6055</eissn><abstract>IntroductionPeople who inject drugs (PWID) have remained a contributor to the consistent HIV incidence rates in the US for decades. Pre-exposure prophylaxis (PrEP) is a promising biomedical intervention for HIV prevention among individuals at risk for HIV infection, including PWID. However, PWID report the lowest rates of PrEP uptake and adherence among at-risk groups. Tailored HIV prevention interventions must include strategies that compensate for cognitive dysfunction among PWID.Methods and analysisUsing the multiphase optimisation strategy, we will be conducting a 16-condition factorial experiment to investigate the effects of four different accommodation strategy components to compensate for cognitive dysfunction among 256 PWID on medication for opioid use disorder. This innovative approach will inform optimisation of a highly effective intervention to enhance PWID’s ability to process and utilise HIV prevention content to improve PrEP adherence and HIV risk reduction in a drug treatment setting.Ethics and disseminationThe institutional review board at the University of Connecticut approved this protocol (H22-0122) with an institutional reliance agreement with APT Foundation Inc. All participants are required to sign an informed consent form prior to engaging in any study protocols. The results of this study will be disseminated on national and international platforms through presentations at major conferences and journals.Trial registration numberNCT05669534.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>37399447</pmid><doi>10.1136/bmjopen-2023-071688</doi><orcidid>https://orcid.org/0000-0002-8681-0252</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2044-6055
ispartof BMJ open, 2023-06, Vol.13 (6), p.e071688-e071688
issn 2044-6055
2044-6055
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8f1612daf38c4c329a45e8cd0321f776
source BMJ Open Access Journals; Publicly Available Content Database; BMJ Journals; PubMed Central
subjects Anti-HIV Agents - therapeutic use
Behavior
Cognitive Dysfunction - drug therapy
Cognitive Dysfunction - prevention & control
Disease prevention
Drug use
Executive function
Factorial experiments
HIV
HIV Infections - drug therapy
HIV Infections - prevention & control
HIV/AIDS
Human immunodeficiency virus
Humans
Infectious disease/HIV
Information processing
Intervention
Memory
Narcotics
Opioid-Related Disorders - drug therapy
Opioid-Related Disorders - prevention & control
Pre-Exposure Prophylaxis - methods
STATISTICS & RESEARCH METHODS
Substance Abuse, Intravenous - epidemiology
Substance misuse
Substance use disorder
title Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A56%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20the%20multiphase%20optimisation%20strategy%20(MOST)%20to%20optimise%20HIV%20prevention%20targeting%20people%20on%20medication%20for%20opioid%20use%20disorder%20(MOUD)%20who%20have%20cognitive%20dysfunction:%20protocol%20for%20a%20MOST%20study&rft.jtitle=BMJ%20open&rft.au=Mistler,%20Colleen%20B&rft.date=2023-06-30&rft.volume=13&rft.issue=6&rft.spage=e071688&rft.epage=e071688&rft.pages=e071688-e071688&rft.issn=2044-6055&rft.eissn=2044-6055&rft_id=info:doi/10.1136/bmjopen-2023-071688&rft_dat=%3Cproquest_doaj_%3E2833023056%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b490t-3078f8fd64fedb51f901dcb0d1927914092695139999024dc51b1cc8296a137a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2831674146&rft_id=info:pmid/37399447&rfr_iscdi=true